Talha Badar: Optimization of venetoclax based therapy

Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center shared on X:

“Wei: Optimization of venetoclax based therapy.

1) use hydrea or flat dose cytarabine to bring WBC below 25k before initiation of Venetoclax.

2) BM biopsy at D21.

3) G-CSF to reduce neutropenic nadir if D21 BM shows blast clearance.

4) MRD clearance may take upto 8 cycles, so continue Ven based regimen if patient is having response.

5) triplet therapy with FLT3i, menin inhibitors etc can reduce risk of Ven resistance.”

Source: Talha Badar/X